Abstract:In order to provide an idea dose of polymyxin B in Chinese patients with renal impairment, the present study collected the clinical data of all patients with renal impairment who received polymyxin B therapy in the intensive care unit (ICU) of The First Affiliated Hospital of Bengbu Medical College (Bengbu, China). The clinical data of six patients treated in the ICU between February 2018 and May 2019 were retrospectively analyzed. All patients had renal impairment and were treated with polymyxin B combination therapy. The patients in the current study received polymyxin B and carbapenem, or polymyxin, carbapenem, cefoperazon and sulbactam, or polymyxin B, carbapenems and aminoglycoside treatment. One patient discontinued treatment. The other five patients received polymyxin B at a dosage of 50 mg every 12 h (100 mg/day) through an intravenous drip. During treatment, four of the five patients had deteriorating renal function to varying degrees, and continuous renal replacement therapy (CRRT) was initiated. Polymyxin B was discontinued in all patients when the infection was controlled. After treatment, four of five patients showed improvement in renal function, and had normal kidney function at the 1-month follow-up evaluation, whereas one patient had chronic renal disease. During hospitalization, one patient experienced neurotoxicity, showing decreased limb muscle strength and cognitive impairment, which might have been caused by polymyxin B, according to the Naranjo adverse drug reactions probability scale (also known as the Naranjo algorithm) score. The present report demonstrated that the administration of 100 mg daily dosage of polymyxin B to the five patients weighing between 50 and 75 kg, could control pulmonary infection during the course of treatment of Chinese patients with renal impairment, however, further research is needed to verify this result. Risk factors for nephrotoxicity and neurotoxicity need to be fully assessed before initiating polymyxin B therapy in patients with renal impairment.

A reappraisal of polymyxin B dosing based on population pharmacokinetic model in patient with renal insufficiency

Use Of Polymyxin B In Patients With Renal Impairment: A Retrospective Examination Of 5 Cases

Pharmacokinetics/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae

Pharmacokinetics/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant <i>Klebsiella pneumoniae</i>

Risk Factors for Polymyxin B-associated Acute Kidney Injury

Risk Factors for Nephrotoxicity Associated with Polymyxin B Therapy in Chinese Patients.

Population Pharmacokinetics of Polymyxin B and Dosage Optimization in Renal Transplant Patients

A population pharmacokinetic model of polymyxin B based on prospective clinical data to inform dosing in hospitalized patients

Population Pharmacokinetics of Polymyxin B and Dosage Strategy in Critically Ill Patients With/without Continuous Renal Replacement Therapy.

Population pharmacokinetic analysis, renal safety, and dosing optimization of polymyxin B in lung transplant recipients with pneumonia: A prospective study

Physiologically Based Pharmacokinetic-Pharmacodynamic Evaluation of Meropenem in CKD and Hemodialysis Individuals

Population pharmacokinetics and clinical outcomes of polymyxin B in paediatric patients with multidrug-resistant Gram-negative bacterial infections.

Pharmacokinetic/pharmacodynamic Adequacy of Polymyxin B Against Extensively Drug-Resistant Gram-negative Bacteria in Critically Ill, General Ward and Cystic Fibrosis Patient Populations.

Population Pharmacokinetics and Limited Sampling Strategies of Polymyxin B in Critically Ill Patients.

Population Pharmacokinetics and Limited Sampling Strategy for Therapeutic Drug Monitoring of Polymyxin B in Chinese Patients With Multidrug-Resistant Gram-Negative Bacterial Infections

Daily fluid intake as a novel covariate affecting the population pharmacokinetics of polymyxin B in patients with sepsis

Pharmacokinetic study of polymyxin B in healthy subjects and subjects with renal insufficiency

Comparing the Population Pharmacokinetics of and Acute Kidney Injury Due to Polymyxin B in Chinese Patients with or Without Renal Insufficiency

A systematic evaluation of population pharmacokinetic models for polymyxin B in patients with liver and/or kidney dysfunction

Population Pharmacokinetics of Polymyxin B: a Systematic Review

Evaluation of polymyxin B AUC/MIC ratio for dose optimization in patients with carbapenem-resistant Klebsiella pneumoniae infection